Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
Microbot Medical (Nasdaq: MBOT) has secured a significant new U.S. patent for its LIBERTY® Endovascular Robotic System, expanding its potential market applications. The patent covers a modular robotic surgical system with interchangeable tool-receiver units, strengthening the company's IP portfolio which now includes 12 granted patents globally and 57 pending applications.
This development could enable LIBERTY® to expand beyond its initial focus on peripheral endovascular procedures (estimated at 2.5 million annual procedures in the U.S.) to potentially reach over 6 million annual endovascular procedures. The company is currently awaiting FDA 510(k) clearance for LIBERTY®, which is notable for being the first fully disposable robotic system in its field.
Microbot Medical (Nasdaq: MBOT) ha ottenuto un nuovo brevetto statunitense importante per il suo Sistema Robotico Endovascolare LIBERTY®, ampliando le possibili applicazioni commerciali. Il brevetto riguarda un sistema chirurgico robotico modulare con unità ricevitrici di strumenti intercambiabili, rafforzando il portafoglio di proprietà intellettuale dell'azienda, che conta ora 12 brevetti concessi a livello globale e 57 domande in attesa.
Questo sviluppo potrebbe permettere a LIBERTY® di estendere il suo impiego oltre le procedure endovascolari periferiche iniziali (stime di 2,5 milioni di interventi annui negli USA) fino a potenzialmente superare i 6 milioni di procedure endovascolari all'anno. L'azienda è in attesa del nulla osta FDA 510(k) per LIBERTY®, noto per essere il primo sistema robotico completamente monouso nel suo settore.
Microbot Medical (Nasdaq: MBOT) ha asegurado una importante nueva patente en EE. UU. para su Sistema Robótico Endovascular LIBERTY®, ampliando sus posibles aplicaciones en el mercado. La patente cubre un sistema quirúrgico robótico modular con unidades receptoras de herramientas intercambiables, reforzando la cartera de propiedad intelectual de la compañía, que ahora incluye 12 patentes concedidas a nivel mundial y 57 solicitudes pendientes.
Este avance podría permitir que LIBERTY® se extienda más allá de su enfoque inicial en procedimientos endovasculares periféricos (estimados en 2,5 millones de procedimientos anuales en EE. UU.) y alcance potencialmente más de 6 millones de procedimientos endovasculares anuales. La compañía está a la espera de la autorización FDA 510(k) para LIBERTY®, destacada por ser el primer sistema robótico completamente desechable en su campo.
Microbot Medical (Nasdaq: MBOT)가 자사의 LIBERTY® 혈관내 로봇 시스템에 대해 미국에서 중요한 신규 특허를 확보하여 시장 적용 가능성을 넓혔습니다. 해당 특허는 교체 가능한 도구 수신 유닛을 갖춘 모듈형 수술용 로봇 시스템을 포함하며, 현재 전 세계 12건의 등록 특허와 57건의 출원 중인 회사의 지식재산 포트폴리오를 강화합니다.
이번 개발로 LIBERTY®는 초기 집중 분야인 말초 혈관내 시술(미국 연간 약 250만 건으로 추정)을 넘어 잠재적으로 연간 600만 건 이상의 혈관내 시술에 도달할 가능성이 있습니다. 회사는 LIBERTY®에 대한 FDA 510(k) 승인 대기 중이며, 이 시스템은 해당 분야에서 최초의 완전 일회용 로봇 시스템으로 주목받고 있습니다.
Microbot Medical (Nasdaq: MBOT) a obtenu un nouveau brevet américain important pour son Système Robotique Endovasculaire LIBERTY®, élargissant ainsi ses applications potentielles sur le marché. Le brevet concerne un système chirurgical robotique modulaire avec des unités réceptrices d'outils interchangeables, renforçant le portefeuille de propriété intellectuelle de la société, qui compte désormais 12 brevets délivrés dans le monde et 57 demandes en cours.
Cette avancée pourrait permettre à LIBERTY® de s'étendre au-delà de son orientation initiale vers les procédures endovasculaires périphériques (estimées à 2,5 millions de procédures annuelles aux États-Unis) et d'atteindre potentiellement plus de 6 millions de procédures endovasculaires par an. La société attend actuellement la clearance FDA 510(k) pour LIBERTY®, reconnu comme le premier système robotique entièrement jetable dans son domaine.
Microbot Medical (Nasdaq: MBOT) hat ein bedeutendes neues US-Patent für sein LIBERTY® Endovaskuläres Robotersystem erhalten und erweitert damit seine potenziellen Marktanwendungen. Das Patent deckt ein modulares, chirurgisches Robotersystem mit austauschbaren Werkzeugaufnahme-Einheiten ab und stärkt das geistige Eigentum des Unternehmens, das nun 12 weltweit erteilte Patente und 57 anhängige Anmeldungen umfasst.
Diese Entwicklung könnte es LIBERTY® ermöglichen, über den ursprünglichen Fokus auf periphere endovaskuläre Eingriffe (geschätzt 2,5 Millionen Eingriffe pro Jahr in den USA) hinauszugehen und potenziell mehr als 6 Millionen endovaskuläre Eingriffe pro Jahr zu erreichen. Das Unternehmen wartet derzeit auf die FDA-510(k)-Freigabe für LIBERTY®, das als das erste vollständig wegwerfbare Robotersystem in seinem Bereich gilt.
- New patent strengthens IP protection for LIBERTY® System in the U.S.
- Potential market expansion from 2.5M to over 6M annual procedures in the U.S.
- System's unique feature as first fully disposable robotic system
- Modular capabilities allow for future adaptability to different clinical needs
- LIBERTY® System still pending FDA 510(k) clearance
- Product not yet available for commercial sale in the U.S.
Insights
Microbot's new patent strengthens LIBERTY® system's market potential, expanding from 2.5M to 6M+ annual procedures while awaiting FDA decision.
This newly granted patent represents a significant intellectual property milestone for Microbot Medical's LIBERTY® Endovascular Robotic System. The patent specifically covers a modular design with interchangeable tool-receiver units that can be independently attached to a base system. This modular architecture is strategically important as it enables the company to potentially expand beyond peripheral procedures to address a much wider range of endovascular applications.
The technical implications are substantial. This modular approach allows for customization across different clinical needs without requiring entirely new systems. From an IP perspective, this brings Microbot's portfolio to 12 granted patents globally with 57 applications pending, creating a strong protective moat around their technology platform.
The market impact is quantifiable and significant. The company currently targets approximately 2.5 million peripheral endovascular procedures annually in the U.S., but this patent potentially enables expansion to over 6 million annual endovascular procedures – representing a 140% increase in addressable market size.
While the company awaits FDA 510(k) clearance decision for LIBERTY®, this patent strengthens their competitive positioning as the first fully disposable robotic system in this space. The disposable nature addresses critical cross-contamination concerns in endovascular procedures while the modular capabilities now create a platform for expansion rather than just a single-application device.
With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending.
The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision.
HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent, covering a modular robotic surgical system which includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably attachable to the base. The Company considers the issuance of this patent to be significant, as it will potentially enable LIBERTY® to be adapted in the future for a wider range of endovascular procedures, which would increase substantially the Total Addressable Market (TAM) the Company is aiming to penetrate. This patent expands the Company’s intellectual property protection in the United States for its LIBERTY® system portfolio, which now includes 12 patents granted globally and 57 patent applications pending.
The patent supports innovation and customization for different clinical needs that would allow the Company to address other indications and significantly increase its potential customer base. The Company now has the flexibility and protection to continue building additional capabilities and features to enhance the LIBERTY® System, with the potential to eventually expand well beyond the estimated 2.5 million peripheral endovascular procedures performed in the U.S. annually.
“We believe LIBERTY® is one of the most advanced and distinctive robotic systems in the world, being the first fully disposable robotic system along with other unique features such as its modular capabilities. This patent recognizes yet another layer of our differentiation and could expand our reach to over 6 million annual endovascular procedures in the U.S. alone,” commented Harel Gadot, Chairman, CEO & President. “Our near-term focus remains on the peripheral market and ensuring our commercial readiness plans in the U.S. are progressing as we await the FDA’s decision.”
LIBERTY® is an investigational device pending FDA 510(k) clearance, and is currently not available for sale in the U.S.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
IR@microbotmedical.com
FAQ
What is the significance of Microbot Medical's (MBOT) new patent for the LIBERTY® System?
How many patents does Microbot Medical (MBOT) now have for the LIBERTY® System?
What makes Microbot Medical's LIBERTY® System unique in the medical device market?
What is the current regulatory status of Microbot Medical's LIBERTY® System?
What is the potential market size for Microbot Medical's LIBERTY® System in the U.S.?
